Supplemental Fig S9 from Phase 2 Study of Zilovertamab Vedotin in Participants with Metastatic Solid Tumors

Key Points

• Plasma concentration profiles indicate the behavior of total ADC over time following treatment.
• The study measures ADC levels after intravenous administration of zilovertamab vedotin every three weeks.
• Observational analysis observes significant changes in plasma concentration, highlighting treatment dynamics.
• These insights contribute to understanding the pharmacokinetics of zilovertamab vedotin in cancer treatment.